Abstract
We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa treated patients with Parkinson’s disease after first time intake of an irreversible monoamine oxidase-B inhibitor. One patient received 10 mg selegiline and eleven patients took 1 mg rasagiline. A significant decrease of monoamine oxidase-B activity appeared 2 and 4 h following monoamine oxidase-B inhibitor intake in comparison to baseline. We confirm with this design, that rasagiline and selegiline inhibit monoamine oxidase-B but not monoamine oxidase-A after single dosing.
References
Bar AO, Amit T, Youdim MB (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169–172
Bartl J, Müller T, Grünblatt E, Gerlach M, Riederer P (2014) Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 121:379–383
Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykko KA, Lammintausta RA (1997) Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 37:602–609
Müller T (2010) The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson’s disease. Clin Med Insights Therap 2:155–168
Müller T, Foley P (2017) Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet 56:251–261
Müller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm 120:761–765
Nag S, Lehmann L, Kettschau G, Toth M, Heinrich T, Thiele A, Varrone A, Halldin C (2013) Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). Bioorg Med Chem 21:6634–6641
Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotoxicology 25:193–204
Riederer P, Laux G (2011) MAO-inhibitors in Parkinson’s Disease. Exp Neurobiol 20:1–17
Riederer P, Müller T (2017) Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol 13:233–240
Treseder SA, Rose S, Summo L, Jenner P (2003) Commonly used l-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Transm (Vienna) 110:229–238
Acknowledgements
We thank the patients and Gabi Öhm, Kathrin Eilert, Marion Marg, Hartmut Rothe, Matthias Küchler, Sven Lütge, Thomas Haas.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This investigation was supported by an unrestricted grant from the "Verein zur Durchführung Neurowissenschaftliche Tagungen e.V.", Würzburg, Germany.
Rights and permissions
About this article
Cite this article
Müller, T., Riederer, P. & Grünblatt, E. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease. J Neural Transm 124, 745–748 (2017). https://doi.org/10.1007/s00702-017-1705-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-017-1705-z